Skip to main content
Premium Trial:

Request an Annual Quote

Silence, Dainippon Expand siRNA Delivery Collaboration

Premium

Silence Therapeutics this week announced that its ongoing siRNA-delivery collaboration with Japan's Dainippon Sumitomo Pharma has been expanded to include additional targets.

The companies' collaboration, which was first announced in September (see RNAi News, 9/3/2009), calls for Silence to “demonstrate the functional delivery” of its proprietary siRNA molecules, in combination with its in-house AtuPlex delivery technology, to undisclosed targets provided by Dainippon.

Under the expanded deal, Silence will continue this work against new targets selected by Dainippon. Financial terms of the arrangement were not disclosed.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.